Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs VXA G1.1 NN (Primary)
- Indications Norovirus infections
- Focus Adverse reactions
- Sponsors Vaxart
- 29 May 2018 Status changed from active, no longer recruiting to completed.
- 04 Mar 2018 Results assessing safety and immunogenicity presented at the 18th International Congress on Infectious Diseases
- 02 Mar 2018 According to Vaxart media release, data from this trial will be presented at the upcoming 18th International Congress on Infectious Diseases (ICID).